Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
30 participants
OBSERVATIONAL
2014-03-31
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Helicobacter pylori(HP) positive
Participants who are diagnosed with Helicobacter Pylori infection through ESD(endoscopic submucosal dissection) will be treated with PPI (proton pump inhibitor).
PPI (proton pump inhibitor)
1. Pre ESD (endoscopic submucosal dissection)
* Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori
* Use of PPI for 2 months
2. Post ESD 1 (After 2 months)
* Assess the distribution of helicobacter pylori after using PPI.
* Stop of PPI
3. Post ESD 2 (After 4 months)
* Assess the distribution of helicobacter pylori after stop of PPI.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PPI (proton pump inhibitor)
1. Pre ESD (endoscopic submucosal dissection)
* Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori
* Use of PPI for 2 months
2. Post ESD 1 (After 2 months)
* Assess the distribution of helicobacter pylori after using PPI.
* Stop of PPI
3. Post ESD 2 (After 4 months)
* Assess the distribution of helicobacter pylori after stop of PPI.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Aged between 19 to 65 years
3. Informed consent
Exclusion Criteria
2. Previous history of PPI use within 6 months
3. No HP infection
19 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Asan Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ji Yong Ahn
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ji Yong Ahn, Professor
Role: PRINCIPAL_INVESTIGATOR
Asan Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asan Medical Center
Seoul, Songpa-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gong EJ, Kim DH, Ahn JY, Na HK, Jung KW, Lee JH, Choi KD, Song HJ, Lee GH, Jung HY, Park Y, Kim MJ. Effects of Proton Pump Inhibitor on the Distribution of Helicobacter pylori and Associated Gastritis in Patients with Gastric Atrophy. Digestion. 2020;101(3):279-286. doi: 10.1159/000499424. Epub 2019 May 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2014-0341
Identifier Type: -
Identifier Source: org_study_id